Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1869809

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1869809

Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Melanoma, Non-Melanoma), By Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests) By End-use, By Region, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 125 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Skin Cancer Diagnostics Market Summary

The global skin cancer diagnostics market size was estimated at USD 9.58 billion in 2024 and is projected to reach USD 15.67 billion by 2033, growing at a CAGR of 5.7% from 2025 to 2033. The integration of artificial intelligence, technological advancements, and patient preference for non-invasive diagnostics drives the growth.

Furthermore, increased awareness about skin cancer, advancements in AI-based diagnostic tools, and initiatives promoting early detection, rising incidence, particularly in sun-exposed regions, are expected to drive the market growth. For instance, according to the American Cancer Society, invasive melanoma accounts for only 1% of all skin cancer cases, and in 2024, an estimated 100,640 new cases of invasive and 99,700 cases of in situ melanoma were diagnosed in the U.S. Partnerships between healthcare providers and tech companies further support this growth by enhancing accessibility and accuracy of diagnoses.

Furthermore, advanced technologies such as AI-enabled product approvals are driving the growth of the market. For instance, in January 2024, the FDA approved the first AI-powered skin cancer diagnostic tool, namely the DermaSensor device. Further, DermaSensor provides quantitative, point-of-testing identification for skin cancer, including melanoma, squamous cell carcinoma, and basal cell carcinoma. Also, the DermaSensor device uses artificial intelligence (AI)-powered spectroscopy in order to identify cellular and subcellular characteristics of lesions.

Modern machine learning techniques rely on extensive datasets to identify patterns useful for classification, with diagnostic imaging being a particularly promising area for AI research. Moreover, skin cancer detection, in particular, is an attractive test type for AI due to the subjective nature of clinical and dermoscopic image interpretation. Also, AI-assisted diagnosis offers advantages such as improved access to specialist expertise, which is often scarce in many regions, leading to long waiting times for specialist appointments. There is growing optimism that AI-based systems could offer greater consistency and higher accuracy than human experts.

Global Skin Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global skin cancer diagnostics market report based on cancer type, test type, end use, and region:

  • Cancer Type Outlook (Revenue, USD Million; 2021 - 2033)
  • Melanoma
  • Non-Melanoma
  • Test Type Outlook (Revenue, USD Million; 2021 - 2033)
  • Dermatoscopy
  • Skin Biopsy
  • Lymph node biopsy
  • Imaging Tests
  • Others
  • End Use Outlook (Revenue, USD Million; 2021 - 2033)
  • Hospital and Clinics
  • Laboratories
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Kuwait
    • UAE
Show more
Product Code: GVR-4-68040-322-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer Type
    • 1.2.2. Test Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Scope & Assessment
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer type and test type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Skin Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements
      • 3.2.1.2. Integration of artificial intelligence
      • 3.2.1.3. Patient preference for non-invasive diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Diagnostic Imaging
  • 3.3. Skin Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Skin Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis

  • 4.1. Global Skin Cancer Diagnostics Market: Cancer Type Dashboard
  • 4.2. Global Skin Cancer Diagnostics Market: Cancer Type Movement Analysis
  • 4.3. Global Skin Cancer Diagnostics Market by Cancer Type, Revenue
  • 4.4. Melanoma
    • 4.4.1. Melanoma market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Non-Melanoma
    • 4.5.1. Non-Melanoma market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Global Skin Cancer Diagnostics Market: Test Type Dashboard
  • 5.2. Global Skin Cancer Diagnostics Market: Test Type Movement Analysis
  • 5.3. Global Skin Cancer Diagnostics Market by Test Type, Revenue
  • 5.4. Dermatoscopy
    • 5.4.1. Dermatoscopy market estimates and forecasts for 2021 to 2033 (USD Million)
  • 5.5. Skin Biopsy
    • 5.5.1. Skin Biopsy market estimates and forecasts for 2021 to 2033 (USD Million)
  • 5.6. Lymph node biopsy
    • 5.6.1. Lymph node biopsy market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Imaging Tests
    • 5.7.1. Imaging Tests market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 6. Skin Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Global Skin Cancer Diagnostics Market: End Use Dashboard
  • 6.2. Global Skin Cancer Diagnostics Market: End Use Movement Analysis
  • 6.3. Global Skin Cancer Diagnostics Market by End Use, Revenue
  • 6.4. Hospital and Clinics
    • 6.4.1. Hospital and Clinics market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Laboratories
    • 6.5.1. Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Analysis market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Skin Cancer Diagnostics Market: Regional Estimates & Trend Analysis by Cancer Type, Test Type, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts for 2021 to 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Castle Bioscience
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. DermTech
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. bioMerieux Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. FOUNDATION MEDICINE, INC.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. DermaSensor, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. F Hoffmann-La Roche Ltd
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. NeoGenomics Laboratories
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Quest Diagnostics Incorporated
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. SkylineDx
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Abbott
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-322-6

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America skin cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 4 North America skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 5 North America skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 6 U.S. skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 7 U.S. skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 8 U.S. skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Canada skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 10 Canada skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 11 Canada skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 12 Mexico skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 13 Mexico skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 14 Mexico skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Europe skin cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 17 Europe skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 18 Europe skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Germany skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 20 Germany skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 21 Germany skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 22 UK skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 23 UK skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 24 UK skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 25 France skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 26 France skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 27 France skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Italy skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 29 Italy skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 30 Italy skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 31 Spain skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 32 Spain skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 33 Spain skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Denmark skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 35 Denmark skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 36 Denmark skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Sweden skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 38 Sweden skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 39 Sweden skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Norway skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 41 Norway skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 42 Norway skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific skin cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 47 China skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 48 China skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 49 China skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Japan skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 51 Japan skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 52 Japan skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 53 India skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 54 India skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 55 India skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 56 South Korea skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 57 South Korea skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 58 South Korea skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Australia skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 60 Australia skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 61 Australia skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 62 Thailand skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 63 Thailand skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 64 Thailand skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Latin America skin cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 67 Latin America skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 68 Latin America skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 69 Brazil skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 70 Brazil skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 71 Brazil skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 72 Argentina skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 73 Argentina skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 74 Argentina skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 75 MEA skin cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 77 MEA skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 78 MEA skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 79 South Africa skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 80 South Africa skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 81 South Africa skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 85 UAE skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 86 UAE skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 87 UAE skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 88 Kuwait skin cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
  • Table 89 Kuwait skin cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 90 Kuwait skin cancer diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Skin cancer diagnostics market: market outlook
  • Fig. 14 Skin cancer diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Skin cancer diagnostics market driver impact
  • Fig. 18 Skin cancer diagnostics market restraint impact
  • Fig. 19 Skin cancer diagnostics market: Cancer Type movement analysis
  • Fig. 20 Skin cancer diagnostics market: Cancer Type outlook and key takeaways
  • Fig. 21 Melanoma market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Non-Melanoma estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Skin cancer diagnostics market: Test Type movement analysis
  • Fig. 24 Skin cancer diagnostics market: Test Type outlook and key takeaways
  • Fig. 25 Dermatoscopy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Skin biopsy estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Lymph node biopsy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Imaging tests market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Others estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Skin cancer diagnostics market: End use movement analysis
  • Fig. 31 Skin cancer diagnostics market: End use outlook and key takeaways
  • Fig. 32 Hospital and clinics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Laboratories estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Others estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Global skin cancer diagnostics market: Regional movement analysis
  • Fig. 36 Global skin cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 37 Global skin cancer diagnostics market share and leading players
  • Fig. 38 North America, by country
  • Fig. 39 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 U.S. key country dynamics
  • Fig. 41 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Canada key country dynamics
  • Fig. 43 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Mexico key country dynamics
  • Fig. 45 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 UK key country dynamics
  • Fig. 48 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Germany key country dynamics
  • Fig. 50 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 France key country dynamics
  • Fig. 52 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Italy key country dynamics
  • Fig. 54 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Spain key country dynamics
  • Fig. 56 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Denmark key country dynamics
  • Fig. 58 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Sweden key country dynamics
  • Fig. 60 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Norway key country dynamics
  • Fig. 62 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 China key country dynamics
  • Fig. 65 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Japan key country dynamics
  • Fig. 67 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 India key country dynamics
  • Fig. 69 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Thailand key country dynamics
  • Fig. 71 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 South Korea key country dynamics
  • Fig. 73 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Australia key country dynamics
  • Fig. 75 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Brazil key country dynamics
  • Fig. 78 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Argentina key country dynamics
  • Fig. 80 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 South Africa key country dynamics
  • Fig. 83 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Saudi Arabia key country dynamics
  • Fig. 85 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 UAE key country dynamics
  • Fig. 87 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Kuwait key country dynamics
  • Fig. 89 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Market share of key market players- Skin cancer diagnostics market
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!